Who is sponsoring NCT03169868?

NCT03169868 is sponsored by Precera Bioscience, Inc..

What drugs are being tested in NCT03169868?

Interventions in NCT03169868: Sano Patient Medication Profile.

What condition does NCT03169868 study?

NCT03169868 studies Mental Disorders.

Is NCT03169868 still recruiting?

NCT03169868 is currently terminated. Last updated 25 January 2019.

Last reviewed 2019-01-25 · How we verify

NCT03169868

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Enhanced Medication Reconciliation For Serious Mental Illness

Terminated NA Last updated 25 January 2019

What this trial tests

NA trial testing Sano Patient Medication Profile in Mental Disorders in 26 participants. Terminated before completion.

Timeline

27 February 2018

Primary endpoint
21 January 2019

21 January 2019

Quick facts

Lead sponsor	Precera Bioscience, Inc.
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	26
Start date	27 February 2018
Primary completion	21 January 2019
Estimated completion	21 January 2019
Sites	1 location across United States

Drugs / interventions tested

Sano Patient Medication Profile

Conditions studied

Mental Disorders — all drugs for Mental Disorders →

Sponsor

Precera Bioscience, Inc.

Who can join

21 and older, any sex, with Mental Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the clinical utility of a decision support tool, the Patient Medication Profile(TM), developed by Sano Informed Prescribing on medication reconciliation and identification of drug-related problems in patients with serious mental illness.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Mental Disorders

Currently open trials in the same condition.

NCT07466875 — Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients · NA · recruiting
NCT06810076 — Developing and Evaluating a Machine-Learning Opioid Overdose Prediction & Risk-Stratification Tool in Primary Care · NA · active not recruiting
NCT06387290 — Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits · Phase 3 · recruiting
NCT06673966 — Immunoinflammatory State Detection and Multimodal Brain Imaging and Electrophysiologic Changes in Schizophrenia · recruiting
NCT06930547 — Effectiveness of Smoking Cessation Education · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03169868 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Precera Bioscience, Inc.
Last refreshed: 25 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03169868.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing